Conduct Study P193: Evaluation of Immune Responses after Priming with Newcastle Disease Virus and Boosting with Trimeric gp145 Proteins from Indian and African Clade C HIV-1 Isolates

点击翻译按钮获取中文摘要

The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers. Specifically this activity will be to evaluate immune responses after priming with Newcastle Disease Virus and boosting with trimeric gp145 Proteins from Indian and African clade C HIV-1 isolates.